AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2007-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 160
- Registration Number
- NCT00255281
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
CMAB vs IMAB in Metastatic Prostate Cancer
Phase 4
Withdrawn
- Conditions
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2007-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00255268
- Locations
- 🇲🇽
Research Site, Mexico City, Mexico
Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00254787
- Locations
- 🇩🇪
Research Site, Werneck, Germany
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT00254735
- Locations
- 🇩🇪
Research Site, Lübeck, Germany
Fast Titration Of Quetiapine Versus Currently Approved Titration
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00254813
- Locations
- 🇳🇴
Research Site, Ålesund, Norway
Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT00254774
- Locations
- 🇩🇪
Research Site, München, Germany
The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT00254800
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00254748
- Locations
- 🇳🇱
Research Site, Veghel, Netherlands
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13
- Registration Number
- NCT00254254
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Safety and Efficacy of Seroquel in First Episode Schizophrenia
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00254241
- Locations
- 🇬🇧
Research Site, London, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath